#Vertex

I wanted to do a quick 2015 update now that I’ve been officially cured of Hepatitis C for more than a year.

Following the release of newer, improved therapies to treat hepatitis C, Vertex has decided to discontinue Incivek (telaprevir).

Vertex will refocus on its cystic fibrosis treatments.

Vertex Pharmaceuticals said its VX-135 and Bristol-Myers Squibb’s daclatasvir likely cured 83 percent of people with genotype 1 of hep C.

Vertex Pharmaceuticals’ hepatitis C antiviral Incivek (telaprevir) has caused a number of deaths due to serious skin reactions.

Here are the top stories by pageviews this year.

Adding a protease inhibitor to pegylated interferon and ribavirin as part of hepatitis C virus (HCV) treatment resulted in higher sustained vi...

Health care providers are being reminded not to prescribe certain cholesterol-reducing medications, notably members of the statin drug class,...

The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted p...

Revised treatment guidelines from the American Association for the Study of Liver Diseases (AASLD) outline a significant change in the standar...

The Fair Pricing Coalition is again sounding the alarm regarding the price of newly approved treatments for hepatitis C.

The U.S. Food and Drug Administration (FDA) has approved a new hepatitis C virus (HCV) treatment called Incivek (telaprevir). The drug, which...

Pharmaceutical companies Merck and Roche have formed a non-exclusive agreement to cooperate on hepatitis C treatment options, Seeking Alpha re...

The Antiviral Drugs Advisory Committee (ADAC) of the U.S. Food and Drug Administration voted 18 to 0 to recommend approval of telaprevir...

The only study completed to evaluate treatment on all major subgroups of people with genotype 1 HCV whose earlier treatment was unsuccessful

Vertex Pharmaceuticals announced on January 20 that the U.S. Food and Drug Administration (FDA) has agreed to expedite its approval review of...